Literature DB >> 1751013

Anti-muscarinic drug effects in a swim-to-platform test: dose-response relations.

C H Vanderwolf1.   

Abstract

Rats were given subcutaneous or intraperitoneal injections of scopolamine, intraperitoneal injections of atropine, or control injections, and trained on a simple swim-to-platform task. Errors were proportional to dose for both drugs over a wide range. No difference was found in the effects of intraperitoneal or subcutaneous scopolamine but scopolamine was 25 times more potent than atropine. The potency of both drugs in impairing swim-to-platform behavior was similar to their potency in abolishing the cholinergic component of neocortical low voltage fast activity. The electrocortical effect of anticholinergic drugs may be a major factor in the behavioral impairment they produce.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751013     DOI: 10.1016/s0166-4328(05)80027-0

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  3 in total

1.  Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.

Authors:  Alison A Williams; Wendy M Ingram; Sarah Levine; Jack Resnik; Christy M Kamel; James R Lish; Diana I Elizalde; Scott A Janowski; Joseph Shoker; Alexey Kozlenkov; Javier González-Maeso; Amelia L Gallitano
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

2.  Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells.

Authors:  Arpita Konar; Navjot Shah; Rumani Singh; Nishant Saxena; Sunil C Kaul; Renu Wadhwa; Mahendra K Thakur
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

3.  Temporal evolution of neurophysiological and behavioral features of synapsin I/II/III triple knock-out mice.

Authors:  Marco Cambiaghi; Marco Cursi; Elena Monzani; Fabio Benfenati; Giancarlo Comi; Fabio Minicucci; Flavia Valtorta; Letizia Leocani
Journal:  Epilepsy Res       Date:  2012-07-28       Impact factor: 3.045

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.